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The Comparison of Optimized MDI Ver-
sus Pumps With or Without Sensors in
Severe Hypoglycemia (HypoCOMPaSS)
trial was a prospective, multicenter,
randomized controlled trial examining
the restoration of impaired awareness
of hypoglycemia (IAH) and the preven-
tion of severe hypoglycemia (SH) in
adults with type 1 diabetes using multi-
ple daily injections (MDI) compared
with continuous subcutaneous insulin
infusion (CSII), with or without adjunc-
tive real-time continuous glucose mon-
itoring (RT-CGM), using a 23 2 factorial
design (1). Few studies are currently
available to compare the difference in
glucose variability (GV) between MDI
and CSII and between self-monitored
blood glucose (SMBG) and RT-CGM (2–
4). These studies showed an improve-
ment in GV in favor of CSII and RT-
CGM. However, none of them included
participants with IAH or history of SH.
The aim of this study is to compare
the changes in GV between MDI and
CSII and between SMBG and RT-CGM
group in this speciﬁc patient group
with type 1 diabetes with IAH or recur-
rent SH.
A total of 96 participants were recruited
for the study. Each participant undertook
7 days of blinded CGM using Medtronic
iPro at baseline and prior to each of the
four weekly visits during the 24-week ran-
domized controlled trial period. GV was
measured as glucose SD and coefﬁcient
of variation (%CV), calculated using avail-
able Excel formulas published online (5).
Overall, there were decreases in GV
between baseline and week 24 mea-
sured by SD (3.9 6 1.0 vs. 3.4 6 0.8
mmol/L, P , 0.001) and %CV (41.3 6
8.0 vs. 36.86 8.1%, P , 0.001).
The MDI group realized improvement
in GV from baseline to week 24 as
measured by SD (3.8 6 1.0 vs. 3.3 6
0.7 mmol/L, P5 0.007) and %CV (42.16
8.4 vs. 36.1 6 6.7%, P 5 0.002). The
CSII group realized similar improve-
ment in SD (4.0 6 1.0 vs. 3.5 6 0.8
mmol/L, P 5 0.005) and %CV (41.7 6
7.2 vs. 37.5 6 9.2%, P 5 0.01). Thus,
CSII and MDI therapy did not differ in
SD and %CV at baseline and week 24.
However, using mixed-effects modeling,
taking into account GV at each time point
and other covariates, CSII appeared to
have a more rapid impact in GV improve-
ment compared with MDI, with an esti-
mated average difference of 23.25 6
0.96% (95% CI 25.15, 21.36) (P 5
0.001) in %CV and a trend toward im-
provement in SD with difference of
20.25 6 0.13 mmol/L (95% CI 20.50,
0.002) (P 5 0.052) (Fig. 1).
The SMBG group realized GV improve-
ment in %CV between baseline and
week 24 (41.3 6 6.9 vs. 37.1 6 6.5%,
P 5 0.005). No differences were seen
in SD (3.8 6 0.9 vs. 3.5 6 0.7 mmol/L,
P 5 0.069). In the RT-CGM group, GV
improvement was seen in both SD
(4.0 6 1.0 vs. 3.4 6 0.8 mmol/L, P ,
0.001) and %CV (42.4 6 8.5 vs. 36.8 6
9.4%, P 5 0.003). SMBG and RT-CGM
groups did not differ at baseline and
week 24. Further, these groups did not
differ when GV was analyzed using
mixed-effects modeling (Fig. 1).
These data suggest that the educational
intervention has played an important part
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in improving GV, although there was no
speciﬁc control group to support this
hypothesis.
In conclusion, we have shown that GV
can be improved within 24 weeks in
adults with long-standing type 1 diabe-
tes complicated by IAH and recurrent
SH. This was seen in all four arms of the
study, suggesting that the education-
based intervention coupled with weekly
health care professional input was
essential.
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